Experienced in Fibrosarcoma

Elisabeth Livingstone

Essen, NW, DE 
Experienced in Fibrosarcoma
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Elisabeth Livingstone practices in Essen, Germany. Ms. Livingstone is rated as an Experienced expert by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Melanoma, Tieche-Jadassohn Nevus, Uveal Melanoma, and Mycosis Fungoides.

Her clinical research consists of co-authoring 185 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Fibrosarcoma.

Gender
Female

Locations

Essen, NW, Germany
Other Locations
Duisburg, NW, Germany
Heidelberg, BW, Germany
Duesseldorf, NW, Germany
Kiel, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase I / II Open Label, Multicentre Study of Encorafenib Plus Binimetinib and PD-1 Antibody Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized Phase I / II Open Label, Multicentre Study of Encorafenib Plus Binimetinib and PD-1 Antibody Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: February 16, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

185 Total Publications

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.
Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.
Journal: Journal for immunotherapy of cancer
Published: August 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Livingstone's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile